Wed, March 13, 2024

Geoff Meacham Maintained (BTAI) at Strong Buy with Decreased Target to $7 on, Mar 13th, 2024

Geoff Meacham of B of A Securities, Maintained "BioXcel Therapeutics, Inc." (BTAI) at Strong Buy with Decreased Target from $8 to $7 on, Mar 13th, 2024.

Geoff has made no other calls on BTAI in the last 4 months.



There are 2 other peers that have a rating on BTAI. Out of the 2 peers that are also analyzing BTAI, 1 agrees with Geoff's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • Colin Bristow of "UBS" Downgraded from Strong Buy to Hold and Decreased Target to $4 on, Wednesday, February 21st, 2024


This is the rating of the analyst that currently disagrees with Geoff


  • Raghuram Selvaraju of "HC Wainwright & Co." Reiterated at Strong Buy and Held Target at $11 on, Wednesday, November 15th, 2023